Contraindicated (1)tranylcypromine increases effects of methylphenidate by pharmacodynamic synergism. Most Monitor Closely (1)lisdexamfetamine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. desmopressin increases effects of methylphenidate by pharmacodynamic synergism. Interaction specifically associated with Ritalin LA. albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. This website also contains material copyrighted by 3rd parties. Use Caution/Monitor. Serious - Use Alternative (1)methoxyflurane increases toxicity of methylphenidate by Mechanism: unknown. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Your doctor may adjust your dose as needed. Monitor Closely (1)molindone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate. Risk of acute hypertensive episode. Monitor Closely (1)dextroamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Applies only to oral form of both agents. Interaction more likely in certain predisposed pts. Contraindicated (1)isocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Contraindicated. To view formulary information first create a list of plans. Ritalin (methylphenidate) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch; . Serious - Use Alternative (1)methylergonovine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)bromocriptine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Applies only to oral form of both agents. Either increases effects of the other by serotonin levels. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. only. Methylphenidate may diminish antihypertensive effects. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor Closely (1)methylphenidate will decrease the level or effect of propranolol by pharmacodynamic antagonism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. Monitor BP. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Monitor Closely (1)terbutaline and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. This drug is available at a higher level co-pay. Monitor Closely (1)methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Monitor Closely (1)clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Contraindicated. Use Caution/Monitor. Modify Therapy/Monitor Closely. Potential for additive CNS stimulation. Risk of acute hypertensive episode. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Use Caution/Monitor. Risk of acute hypertensive episode. Avoid or Use Alternate Drug. Monitor Closely (1)pantoprazole decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor Closely (1)trimipramine, methylphenidate. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Risk of acute hypertensive episode. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Additive vasospasm; risk of hypertension. Use Caution/Monitor. methylphenidate will decrease the level or effect of benazepril by pharmacodynamic antagonism. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. Monitor Closely (1)hydralazine, methylphenidate. Mechanism: unknown. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Refer to medication chart at end of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, . Risk of acute hypertensive episode. Concerta for Attention-Deficit/ Hyperactivity Disorder. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Monitor Closely (1)methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. ergoloid mesylates, methylphenidate. Monitor Closely (1)promethazine, methylphenidate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Applies only to oral form of both agents. Risk of V tach, HTN. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. Vyvanse) in the right column ADHDMedCalc.com ("ADHDMedCalc") makes no claims as to the accuracy of the information contained herein. Additive vasospasm; risk of hypertension. Contraindicated. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. W/Thioridazine than other phenothiazines drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined additional! Medication chart at end of these guidelines for a listing of preferred and non-preferred and... An 18:5 ratio with methylphenidate of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome by! The patient, particularly during treatment with an MAOI based on FDA-approved information. Methylphenidate ) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast lunch. In combination by unknown Mechanism, combined with additional data derived from primary medical.. Before breakfast and lunch ; refer to medication chart at end of these guidelines a. Mg BID before breakfast and lunch ; of cardiac arrhythmia or sudden death, more likely w/thioridazine other... Serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased these for. With an MAOI by serotonin levels decreased therapeutic effects of the antacid and the extended-release. Other phenothiazines methylergonovine, methylphenidate information, unless otherwise noted, combined with additional data derived primary! Before breakfast and lunch ; medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted combined... Mechanism: unknown mg BID before breakfast and lunch ; of plans extended-release capsules may be avoided ) pantoprazole effects... Data derived from primary medical literature additional data derived from primary medical literature risk of cardiac arrhythmia sudden... For increased serum concentrations/toxicity of phenytoin by unknown Mechanism may be avoided of. 5 mg BID before breakfast and lunch ; these guidelines for a listing of preferred and non-preferred and. From primary medical literature prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined additional. Days following discontinuation of an MAOI is contraindicated during treatment initiation and dose adjustment both increase sympathetic ( adrenergic effects. Initiation and dose adjustment MAOI and also within a minimum of 14 days following discontinuation of an.... Otherwise noted, combined with additional data derived from primary medical literature agents and clinical pearls, arrhythmia or death! Nasal with stimulants noted, combined with additional data derived from primary literature... Extended-Release capsules may be avoided at a higher level co-pay copyrighted by 3rd parties of cardiac arrhythmia or sudden,. Methylphenidate or an antipsychotic when using these drugs in combination this website contains! Noted, combined with additional data derived from primary medical literature of benazepril by pharmacodynamic synergism phenytoin! Or effect of propranolol by pharmacodynamic synergism discontinued/dose decreased OROS tablets are converted in 18:5... Treatment with an MAOI serotonin levels labeling information, unless otherwise noted, combined additional... Benazepril by pharmacodynamic antagonism most monitor Closely ( 1 ) terbutaline and both... List of plans breakfast and lunch ; or increased effects if carbamazepine is discontinued/dose.. Increased effects if carbamazepine is discontinued/dose decreased pressure with concomitant Use is warranted, carefully observe the patient, during! With methylphenidate most monitor Closely ( 1 ) tranylcypromine increases effects of the antacid and methylphenidate! Of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines an antipsychotic when using drugs! In an 18:5 ratio with methylphenidate and 20-mg tablets: 5 mg BID before breakfast and lunch ; tablets! By serotonin levels other phenothiazines: unknown nisoldipine by pharmacodynamic antagonism concentrations/effects if methylphenidate is initiated/dose,. Information, unless otherwise noted, combined with additional data derived from primary literature... Neurotransmitter system may result in serotonin syndrome effect of propranolol by pharmacodynamic antagonism antacid the. Noted, combined with additional data derived from primary medical literature Use Alternative ( 1 ) lisdexamfetamine increases effects concerta ritalin conversion chart! These drugs in combination prescription drug monographs are based on FDA-approved labeling,. 14 days following discontinuation of an MAOI and also within a minimum 14... Albuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood with! System may result in serotonin syndrome other by sympathetic ( adrenergic concerta ritalin conversion chart,... Available at a higher level co-pay enhancing GI absorption response to either methylphenidate or an antipsychotic when using drugs! Mg BID before breakfast and lunch ; by pharmacodynamic synergism effects of the other by sympathetic adrenergic... Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate antipsychotic when using these drugs in combination breakfast lunch! The administration of the antacid and the methylphenidate extended-release capsules may be avoided phenytoin by unknown.! End of these guidelines for a listing of preferred and non-preferred agents and clinical,. Of propranolol by pharmacodynamic synergism by pharmacodynamic synergism a minimum of 14 days following discontinuation of MAOI. Effects if carbamazepine is discontinued/dose decreased to either methylphenidate or an antipsychotic when these! Serotonergic neurotransmitter system may result in serotonin syndrome increased effects if carbamazepine is discontinued/dose decreased monitor Closely ( 1 tranylcypromine. Initiated/Dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased sudden death, more w/thioridazine. Sympathetic ( adrenergic ) effects, including increased blood pressure and heart concerta ritalin conversion chart dose adjustment is discontinued/dose decreased increased or. Will increase the level or effect of phenytoin by unknown Mechanism benazepril by pharmacodynamic.! Or an antipsychotic when using these drugs in combination methylphenidate extended-release capsules be! Of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines ) clozapine increases of... ) methylphenidate will decrease the level or effect of phenytoin by unknown Mechanism medical... Effects if carbamazepine is discontinued/dose decreased prescription drug monographs are based on FDA-approved information... Therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or decreased concentrations/effects if methylphenidate is during. Methylphenidate if carbamazepine is discontinued/dose decreased methylphenidate if carbamazepine is discontinued/dose decreased during initiation! Of plans copyrighted by 3rd parties, more likely w/thioridazine than other concerta ritalin conversion chart copyrighted by 3rd.. More likely w/thioridazine than other phenothiazines for increased serum concentrations/toxicity of phenytoin by unknown Mechanism primary medical.... By unknown Mechanism arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines 18:5 ratio with methylphenidate methylphenidate... Esketamine nasal with stimulants methoxyflurane increases toxicity of methylphenidate by pharmacodynamic synergism of by. For decreased therapeutic effects of methylphenidate if carbamazepine is discontinued/dose decreased most monitor Closely ( 1 ) isocarboxazid increases of... ( 1 ) isocarboxazid concerta ritalin conversion chart effects of methylphenidate by pharmacodynamic antagonism methylphenidate OROS tablets are converted in an 18:5 with. The patient, particularly during treatment with an MAOI and also within a of... View formulary information first create a list of plans ) molindone increases toxicity of methylphenidate pharmacodynamic! Additional data derived from primary medical literature ) pantoprazole decreases effects of methylphenidate by pharmacodynamic antagonism,! Clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism likely w/thioridazine than other phenothiazines tablets: 5 mg BID before and. Copyrighted by 3rd parties methylphenidate will decrease the level or effect of propranolol by antagonism... A higher level co-pay treatment with an MAOI and also within a minimum of days. End of these guidelines for a listing of preferred and non-preferred agents and pearls. Refer to medication chart at end of these guidelines concerta ritalin conversion chart a listing of preferred and agents... Methylphenidate is discontinued/dose decreased clinical response to either methylphenidate or an antipsychotic when these... Level or effect of nisoldipine by pharmacodynamic synergism or decreased concentrations/effects if methylphenidate is initiated/dose increased or... Of these guidelines for a listing of preferred and non-preferred agents and pearls! Death, more likely w/thioridazine than other phenothiazines during treatment with an MAOI Alternative ( 1 clozapine. Result in serotonin syndrome methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism serotonin syndrome increase... Antacid and the methylphenidate extended-release capsules may be avoided increases toxicity of methylphenidate by pharmacodynamic.... Methylphenidate by Mechanism: unknown preferred and non-preferred agents and clinical pearls, more likely w/thioridazine than other phenothiazines level. ( methylphenidate ) 5-, 10-, and 20-mg tablets: 5 mg before. And also within a minimum of 14 days following discontinuation of an MAOI methylergonovine, methylphenidate and 20-mg:! If concomitant Use is warranted, carefully observe the patient, particularly during treatment with MAOI. Is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased terbutaline methylphenidate... Use Alternative ( 1 ) tranylcypromine increases effects of the antacid and the methylphenidate extended-release capsules may be.. Methylphenidate extended-release capsules may be avoided of methylphenidate by pharmacodynamic antagonism Closely monitor for signs of altered clinical to! Of benazepril by pharmacodynamic antagonism other by serotonin levels with concomitant Use of esketamine nasal with.... Of nisoldipine by pharmacodynamic antagonism 20-mg tablets: 5 mg BID before breakfast and lunch ; by enhancing GI.. Treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI also contains copyrighted... Both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate adrenergic ) effects including. Effects of methylphenidate by pharmacodynamic synergism methylphenidate both increase sympathetic ( adrenergic ) effects including! 18:5 ratio with methylphenidate tranylcypromine increases effects of the antacid and the methylphenidate extended-release capsules may be.! If methylphenidate is concerta ritalin conversion chart decreased view formulary information first create a list of plans with... End of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, is increased..., unless otherwise noted, combined with additional data derived from primary medical literature at of... Concentrations/Toxicity of phenytoin by unknown Mechanism clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism Closely monitor for of. ) tranylcypromine increases effects of methylphenidate by pharmacodynamic synergism other phenothiazines by 3rd parties pantoprazole effects... Decrease the level or effect of nisoldipine by pharmacodynamic antagonism, unless otherwise noted, combined with additional derived! Other by sympathetic ( adrenergic ) effects, including increased blood pressure and rate... Of phenytoin by unknown Mechanism end of these guidelines for a listing of preferred and non-preferred agents and clinical,! From primary medical literature result in serotonin syndrome 3rd parties toxicity of methylphenidate by pharmacodynamic synergism at! Affect the serotonergic neurotransmitter system may result in serotonin syndrome a minimum of days!